Biotech Values

[WorstLuck]

https://investors.ocutx.com/events/event-details/ocular-therapeutix-2024-investor-day

It has been linked in other posts, including a prior 'sticky'.

One conflict I have seen in the slides regarding "at risk".

https://investors.ocutx.com/static-files/9a2366eb-bf3f-45d8-b6f4-8aad4928c536

#57 says final design pending FDA Type C feedback, while #47 footnote 1. states the trial is being initiated prior to the type C meeting.

Although it may not actually be a conflict as the trial could be initiated but not started, as happened with Sol-1 last year and then the trial was modified with a new SPA. So both may be accurate!

My recollection from other parts of the presentation was in alignment with slide #57.

Lastly, regulatory risk is primarily due to no SPA and no one having yet had a drug approved under the new guidelines. I don't consider the risk to be much different than many other FDA approvals, again waiting to see if there are significant design changes or warning more strongly worded.